

Belgium: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2015 (n/100,000 person years)

Belgium: Females 2015	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI
C00 Lip	20	0.3	-	-	-	-	-	-	-	-	0.3	0.5	0.5	-	0.3	0.9	0.4	2.6	2.5	0.4	0.2	0.2	0.01
C01 Base of tongue	36	-	-	-	-	-	-	-	0.6	-	1.0	0.7	1.6	1.5	2.3	0.9	0.4	2.6	0.5	0.6	0.5	0.4	0.04
C02 Tongue	99	-	-	-	-	-	-	-	0.6	0.8	1.5	2.2	4.5	3.0	5.2	3.9	4.9	4.6	3.5	1.7	1.3	0.9	0.11
C03 Gum	42	-	-	-	-	-	-	-	-	-	0.8	-	1.1	1.5	2.6	2.2	1.8	2.6	4.0	0.7	0.5	0.3	0.04
C04 Floor of mouth	55	-	-	-	-	-	-	-	-	-	0.8	1.2	3.4	4.5	2.6	1.3	0.4	0.5	3.0	1.0	0.8	0.6	0.07
C05 Palate	39	-	-	-	-	0.6	-	-	-	0.5	1.0	0.7	1.9	2.4	2.3	0.9	1.3	0.5	-	0.7	0.6	0.4	0.05
C06 Mouth, NOS	43	-	-	-	-	0.3	-	-	0.3	0.5	-	-	0.5	0.9	3.6	3.9	3.1	2.1	1.5	0.8	0.5	0.4	0.05
C07 Parotid gland	44	-	-	-	-	-	-	0.5	0.6	0.3	0.5	1.5	1.6	0.6	1.0	3.9	2.7	2.1	0.5	0.8	0.6	0.4	0.05
C08 Salivary glands, NOS	13	-	-	-	-	-	0.3	-	-	-	-	0.7	-	-	0.7	1.3	0.4	0.5	1.0	0.2	0.2	0.1	0.01
C09 Tonsil	81	-	-	-	-	-	-	-	-	0.5	0.8	2.7	2.9	5.9	5.2	3.5	2.2	1.0	1.5	1.4	1.1	0.8	0.11
C10 Oropharynx	55	-	-	-	-	-	-	-	-	0.3	0.5	0.7	2.4	4.8	3.9	1.7	1.3	2.1	0.5	1.0	0.7	0.5	0.07
C11 Nasopharynx	19	0.3	-	-	-	-	0.6	0.5	0.6	0.8	0.5	0.5	0.3	0.3	0.3	0.4	-	0.5	-	0.3	0.3	0.3	0.03
C12 Pyriform sinus	34	-	-	-	-	-	-	-	-	0.3	0.5	0.7	2.6	2.4	1.6	0.9	-	-	1.5	0.6	0.5	0.4	0.05
C13 Hypopharynx	12	-	-	-	-	-	-	-	-	-	-	0.2	0.5	1.2	0.7	0.4	-	0.5	0.5	0.2	0.2	0.1	0.02
C14 Lip, oral cavity and pharynx, NOS	9	-	-	-	-	-	-	-	-	-	-	-	-	0.3	0.7	0.4	0.9	1.5	-	0.2	0.1	0.1	0.01
C15 Oesophagus	276	-	-	-	-	-	-	0.3	0.3	-	1.0	2.7	7.1	13.7	15.3	14.9	16.1	17.9	17.1	4.8	3.1	2.2	0.28
C16 Stomach	526	-	-	-	-	-	0.6	0.3	2.2	4.2	5.9	5.9	9.0	16.0	17.3	19.7	39.4	38.4	51.9	9.2	5.7	3.9	0.40
C17 Small intestine	136	-	-	-	-	-	-	-	2.5	0.8	1.3	1.5	4.0	3.0	7.5	5.2	8.1	9.2	8.6	2.4	1.6	1.1	0.13
C18 Colon	2,857	-	-	1.0	2.3	2.3	4.5	4.4	6.4	9.6	18.9	27.9	54.0	93.0	105.8	131.2	189.8	233.2	271.9	50.1	30.3	20.7	2.28
C19 Rectosigmoid junction	64	-	-	-	-	-	-	-	-	-	0.5	1.0	1.6	2.1	2.0	5.7	5.8	3.1	3.5	1.1	0.7	0.5	0.06
C20 Rectum	919	-	-	-	-	0.3	0.6	1.4	2.5	5.3	6.6	13.8	25.4	36.0	30.0	52.9	60.9	64.1	54.9	16.1	10.6	7.3	0.87
C21 Anus and anal canal	130	-	-	-	-	-	-	-	0.3	1.1	2.0	2.5	6.1	4.2	5.9	6.1	3.6	8.2	7.1	2.3	1.6	1.1	0.14
C22 Liver and intrahepatic bile ducts	263	0.3	-	-	-	0.3	-	0.3	-	1.9	1.3	4.7	2.6	10.1	14.0	19.2	16.6	15.9	15.1	4.6	3.1	2.1	0.27
C23 Gallbladder	58	-	-	-	-	-	-	-	-	-	0.3	0.2	1.1	1.5	3.3	3.5	2.2	6.2	6.0	1.0	0.6	0.4	0.05
C24 Biliary tract, NOS	134	-	-	-	-	-	0.3	-	-	0.3	0.3	1.2	1.6	2.7	5.5	5.7	11.2	17.4	11.1	2.3	1.3	0.8	0.09
C25 Pancreas	879	-	-	0.7	-	1.2	0.3	1.4	2.2	3.4	3.8	10.4	17.2	22.0	42.3	56.0	66.2	64.1	59.9	15.4	9.7	6.6	0.80
C26 Other ill-defined digestive organs	12	-	-	-	-	-	-	-	0.3	-	0.3	-	-	0.9	-	0.9	0.9	0.5	1.0	0.2	0.1	0.1	0.01
C30 Nasal cavity and middle ear	16	-	-	-	-	-	-	-	0.8	0.3	0.5	-	0.8	0.6	-	-	0.9	0.5	1.0	0.3	0.2	0.2	0.01
C31 Accessory sinuses	21	-	-	-	0.3	-	-	0.3	-	0.3	0.5	0.5	0.5	0.6	0.7	0.4	0.9	0.5	2.0	0.4	0.3	0.2	0.02
C32 Larynx	94	-	-	-	-	-	-	-	0.6	0.3	1.3	1.5	2.1	5.6	5.5	7.9	2.7	3.1	3.0	1.6	1.2	0.9	0.12
C33 Trachea	3	-	-	-	-	-	-	-	-	-	0.3	0.2	-	-	-	-	-	-	0.5	0.1	0.0	0.0	0.00
C34 Bronchus and lung	2,658	-	-	-	0.3	-	0.8	1.1	2.2	8.0	21.2	46.4	94.4	140.3	149.8	153.1	135.2	128.1	75.5	46.6	33.6	23.7	3.04
C37 Thymus	18	-	-	-	-	-	0.3	-	0.3	-	-	-	1.1	0.6	1.0	2.2	0.4	-	0.5	0.3	0.3	0.2	0.03
C38 Heart, mediastinum and pleura	6	-	0.3	-	-	-	-	-	-	0.3	-	-	-	-	-	-	-	0.4	0.5	1.0	0.1	0.1	0.00
C39 Respiratory system and intrathoracic organs, NOS	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.4	-	0.5	0.0	0.0	-
C40 Bone and articular cartilage of limbs	36	-	1.9	0.3	0.3	0.6	-	-	0.3	1.1	1.5	0.7	0.5	0.9	0.7	0.4	-	1.0	1.0	0.6	0.6	0.6	0.05
C41 Bone and articular cartilage, NOS	29	0.3	-	1.0	0.3	0.3	-	0.3	-	0.5	0.5	0.5	0.5	1.2	1.0	2.2	-	1.0	-	0.5	0.5	0.4	0.04
C43 Malignant melanoma of skin	1,632	-	0.3	-	2.3	7.3	17.1	19.7	21.1	38.7	40.8	47.7	43.1	44.9	44.0	57.7	53.7	54.3	42.3	28.6	24.0	18.8	1.91
C44 Malignant neoplasms of skin	2,728	-	0.3	-	0.3	1.7	2.5	2.2	2.8	7.4	14.3	22.2	32.8	45.8	86.0	122.9	188.9	252.2	393.8	47.8	25.4	16.4	1.69

Belgium: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2015 (n/100,000 person years)

Belgium: Females 2015	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRi
C45 Mesothelioma	63	-	-	-	-	-	-	-	0.3	0.5	-	0.5	1.6	1.5	4.2	1.7	4.0	5.1	5.5	1.1	0.7	0.5	0.05
C46 Kaposi's sarcoma	9	-	-	-	-	-	-	-	0.3	-	0.3	0.5	-	0.3	-	0.4	0.4	-	1.0	0.2	0.1	0.1	0.01
C47,C49 Soft tissues	167	1.9	-	0.3	0.7	0.3	1.1	0.5	2.2	1.3	1.5	3.0	3.4	5.3	5.9	6.6	7.2	13.3	7.1	2.9	2.2	1.7	0.17
C48 Retroperitoneum and peritoneum	48	1.0	-	-	-	-	-	-	0.3	-	0.8	1.5	0.8	0.9	2.6	4.4	1.8	2.6	1.0	0.8	0.7	0.5	0.06
C50 Breast	10,378	-	-	-	0.3	2.6	11.2	38.6	84.0	148.0	247.7	290.6	317.4	386.9	429.5	419.0	414.9	396.2	352.5	181.9	141.5	104.1	11.20
C51 Vulva	218	-	-	-	-	-	0.8	0.8	1.1	2.1	1.8	4.2	5.0	5.1	9.1	6.6	12.5	19.0	16.1	3.8	2.5	1.7	0.18
C52 Vagina	42	0.3	-	-	-	-	0.3	0.3	-	-	0.3	1.2	0.8	1.8	1.6	0.9	2.7	1.5	4.0	0.7	0.5	0.4	0.04
C53 Cervix uteri	634	-	-	-	-	0.3	7.0	12.1	19.2	20.7	24.7	13.8	13.2	14.9	12.4	18.4	14.3	14.4	12.1	11.1	10.0	8.0	0.78
C54 Corpus uteri	1,458	-	-	-	-	-	-	0.5	3.9	6.6	8.2	20.7	40.2	60.9	80.1	94.9	87.3	85.1	60.4	25.6	17.5	12.1	1.57
C55 Uterus	8	-	-	-	-	-	-	-	-	0.3	0.3	-	-	0.6	-	-	0.4	1.0	0.5	0.1	0.1	0.1	0.01
C56 Ovary	807	-	0.3	0.3	1.6	1.7	2.0	1.6	3.1	6.9	9.2	15.6	17.7	28.2	35.2	47.7	49.2	45.1	34.2	14.1	10.1	7.3	0.85
C57 Female genital organs, NOS	91	-	-	-	-	-	0.3	-	0.6	0.5	0.5	1.5	2.6	3.9	3.6	6.6	7.2	2.1	4.5	1.6	1.1	0.8	0.10
C58 Placenta	3	-	-	-	-	-	0.3	-	0.3	0.3	-	-	-	-	-	-	-	-	-	0.1	0.1	0.1	0.00
C64 Kidney	586	2.6	-	-	0.7	-	0.6	1.6	3.1	5.3	5.1	9.4	13.2	19.3	28.7	33.2	40.7	35.9	19.6	10.3	7.3	5.3	0.61
C65 Renal pelvis	77	-	-	-	-	-	-	-	-	-	0.3	0.5	1.1	3.0	2.6	4.4	5.4	9.2	6.0	1.3	0.8	0.5	0.06
C66 Ureter	61	-	-	-	-	-	-	-	-	-	-	0.5	1.1	1.5	3.3	2.2	5.8	5.6	5.5	1.1	0.6	0.4	0.04
C67 Bladder	508	-	-	-	-	-	-	-	0.3	1.6	2.3	3.2	6.1	14.0	19.2	24.9	36.7	48.7	58.4	8.9	4.9	3.2	0.36
C68 Urinary organs, NOS	10	-	-	-	-	-	-	-	-	-	-	-	-	0.3	1.0	-	1.3	1.0	0.5	0.2	0.1	0.1	0.01
C69 Eye and adnexa	52	0.6	0.3	-	-	-	0.3	-	-	0.3	1.0	1.2	1.9	1.5	0.7	3.1	2.7	2.1	3.5	0.9	0.7	0.5	0.05
C70 Meninges	13	-	-	-	-	-	-	-	-	-	0.8	0.2	0.3	0.6	0.7	0.4	0.9	0.5	-	0.2	0.2	0.1	0.01
C71 Brain	328	2.2	1.6	1.3	1.6	2.6	2.2	2.5	2.8	4.5	4.8	6.4	9.8	11.6	14.0	12.7	12.1	10.3	7.1	5.8	4.8	4.0	0.40
C72 Spinal cord, cranial nerves and CNS, NOS	15	0.3	0.3	-	0.3	-	-	0.5	-	0.3	0.8	0.5	0.3	0.9	-	-	-	-	-	0.3	0.3	0.3	0.02
C73 Thyroid gland	739	-	-	0.7	2.9	5.8	10.6	13.4	17.8	22.5	19.4	19.8	25.7	20.5	18.9	16.6	11.2	9.2	5.5	13.0	12.1	9.9	0.97
C74 Adrenal gland	47	1.3	-	-	-	-	0.6	0.3	0.6	0.5	0.8	1.2	2.6	1.8	1.6	0.4	1.8	0.5	0.5	0.8	0.7	0.6	0.06
C75 Endocrine glands, NOS	19	-	-	-	0.3	0.6	0.3	-	0.6	0.5	-	-	0.5	-	1.6	0.4	0.9	0.5	-	0.3	0.3	0.3	0.02
C81 Hodgkin's disease	151	-	0.6	1.3	4.9	8.2	5.9	3.8	1.7	2.1	1.3	1.5	1.3	0.6	3.9	3.9	3.6	1.5	1.5	2.6	2.7	2.7	0.20
C82-C86 Non-Hodgkin-lymphoma	885	0.3	0.3	0.3	1.3	2.6	2.5	2.5	1.9	6.1	7.1	13.6	18.5	27.6	37.4	41.1	63.6	59.5	54.4	15.5	10.3	7.4	0.81
C88 Malignant immunoproliferative diseases	149	-	-	-	-	-	0.6	0.5	0.6	0.8	0.5	1.7	3.2	3.6	5.2	9.2	12.1	11.8	10.1	2.6	1.6	1.1	0.13
C90 Multiple myeloma	362	-	-	-	-	-	0.3	-	-	2.4	3.8	5.9	6.6	8.3	14.0	26.2	24.2	29.7	22.7	6.3	4.0	2.7	0.34
C91 Lymphoid leukaemia	469	5.7	2.5	1.3	0.7	2.3	0.6	0.3	1.4	1.3	2.3	6.7	7.9	17.2	19.2	20.1	37.1	32.3	20.6	8.2	5.8	4.6	0.45
C92 Myeloid leukaemia	297	1.6	0.6	0.7	1.3	1.5	2.2	1.1	1.9	2.1	6.1	4.4	5.6	6.5	9.4	12.2	12.1	20.0	22.2	5.2	3.7	3.0	0.29
C93 Monocytic leukaemia	62	0.3	-	-	0.3	-	0.8	-	-	0.3	-	-	0.8	1.2	1.6	3.5	5.4	8.2	4.0	1.1	0.6	0.5	0.04
C94-C95 Leukaemia other	14	0.3	0.3	-	-	-	0.3	0.3	-	-	-	0.5	-	-	-	0.4	0.9	1.5	1.0	0.2	0.2	0.2	0.01
C96 Lymphoid, haematopoietic and related tissue, NOS	26	1.3	0.3	-	0.3	0.3	-	0.3	1.4	0.3	1.0	-	0.3	0.6	0.7	-	0.4	0.5	0.5	0.5	0.5	0.5	0.03
C76 Other and ill-defined sites	10	-	-	-	-	-	-	-	-	-	-	0.2	-	-	0.7	0.4	0.4	1.0	1.5	0.2	0.1	0.1	0.01
C80 Unknown primary site	439	-	-	-	-	-	-	-	1.9	1.6	2.8	4.2	7.4	14.0	16.6	18.8	29.5	36.4	46.3	7.7	4.5	3.0	0.34
MPD Myeloproliferative Disorders	381	-	-	-	-	0.3	0.6	1.4	1.9	2.1	3.8	3.7	6.6	11.3	16.9	21.9	25.5	25.6	28.2	6.7	4.3	3.0	0.35
MDS Myelodysplastic syndromes	382	0.3	0.6	-	0.3	0.3	0.6	1.1	1.7	0.8	2.8	1.7	5.3	7.4	10.1	20.1	30.4	39.5	38.8	6.7	3.8	2.6	0.27
Total	34,106	21.4	10.7	9.3	23.8	44.2	79.5	116.7	202.0	330.0	493.0	644.4	857.9	1,158.1	1,382.4	1,578.0	1,791.1	1,919.7	1,907.5	597.9	424.6	308.0	29.36
Total excl. non-melanoma	31,378	21.4	10.4	9.3	23.4	42.5	77.0	114.5	199.2	322.6	478.7	622.2	825.1	1,112.4	1,296.4	1,455.1	1,602.2	1,667.5	1,513.7	550.1	399.2	291.6	28.14
Total excl. non-melanoma and MDS, MPD	30,615	21.1	9.8	9.3	23.1	41.9	75.9	112.1	195.6	319.7	472.1	616.8	813.2	1,093.6	1,269.4	1,413.1	1,546.3	1,602.4	1,446.8	536.7	391.1	286.0	27.70

CR: crude (all ages) incidence rate (n/100,000 person years)

ESR and WSR: age standardised incidence rate, using the European or World Standard Population (n/100,000 person years)

CRi: Cumulative Risk (0-74 years)